GGrantIndex
← Leaderboards

Jennifer R Cochran

Massachusetts Institute Of Technology

$6,620,716
Attributed
$9,301,930
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $886.7K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,301,930 · 9

By mechanism

R01$4,427,848 · 2
T32$2,930,624 · 2
R21$1,108,519 · 3
K01$748,466 · 1
F32$86,473 · 1

Top collaborators

Most similar at Massachusetts Institute Of Technology

Same institution · by research overlap

Others in their field

Top investigators on “Ligands

Research focus

LigandsReceptorTumorBaseProteinsMalignant NeoplasmsProtein EngineeringAffinityEngineeringMutantPropertyMediatingNeoplastic CellSurfaceTherapeutic InterventionBiologicalSignal PathwaySignal TransductionBinding (Molecular Function)Neoplasm MetastasisCancer TherapyCombinatorialLibrariesTumor Growth

Grant awards (34)

Graduate Training Program in Biotechnology$321,270
T32 · FY2025 · GM · contact PI
Graduate Training Program in Biotechnology$329,616
T32 · FY2024 · GM · contact PI
Graduate Training Program in Biotechnology$318,321
T32 · FY2023 · GM · contact PI
Development of novel protein-based therapeutics for lung cancer$552,581
R01 · FY2022 · CA
Graduate Training Program in Biotechnology$312,217
T32 · FY2022 · GM · contact PI
Development of novel protein-based therapeutics for lung cancer$563,856
R01 · FY2021 · CA
Graduate Training Program in Biotechnology$292,577
T32 · FY2021 · GM · contact PI
Development of novel protein-based therapeutics for lung cancer$563,401
R01 · FY2020 · CA
Graduate Training Program in Biotechnology$231,570
T32 · FY2020 · GM · contact PI
Development of novel protein-based therapeutics for lung cancer$557,605
R01 · FY2019 · CA
Graduate Training Program in Biotechnology$285,968
T32 · FY2019 · GM · contact PI
Development of novel protein-based therapeutics for lung cancer$603,877
R01 · FY2018 · CA
Graduate Training Program in Biotechnology$282,780
T32 · FY2018 · GM · contact PI
Graduate Training Program in Biotechnology$279,669
T32 · FY2017 · GM · contact PI
Graduate Training Program in Biotechnology$276,636
T32 · FY2016 · GM · contact PI
Engineering a multispecific receptor antagonist to inhibit cancer metastasis$173,934
R21 · FY2015 · CA · contact PI
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapy$312,514
R01 · FY2014 · CA · contact PI
Engineering a multispecific receptor antagonist to inhibit cancer metastasis$208,258
R21 · FY2014 · CA · contact PI
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapy$302,335
R01 · FY2013 · CA · contact PI
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapy$321,101
R01 · FY2012 · CA · contact PI
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapy$320,588
R01 · FY2011 · CA · contact PI
Engineering high affinity tumor-targeting peptides against carbonic anhydrase IX$200,902
R21 · FY2011 · CA · contact PI
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapy$329,990
R01 · FY2010 · CA · contact PI
Engineering high affinity tumor-targeting peptides against carbonic anhydrase IX$171,403
R21 · FY2010 · CA · contact PI
Engineering the Met receptor: a potent antagonist of tumor growth and metastasis$168,888
R21 · FY2009 · CA · contact PI
Engineering the Met receptor: a potent antagonist of tumor growth and metastasis$185,134
R21 · FY2008 · CA · contact PI
Engineering high affinity integrin binding proteins$143,291
K01 · FY2008 · CA · contact PI
Engineering high affinity integrin binding proteins$155,420
K01 · FY2007 · CA · contact PI
Engineering high affinity integrin binding proteins$159,462
K01 · FY2006 · CA · contact PI
Engineering high affinity integrin binding proteins$159,462
K01 · FY2005 · CA
Engineering high affinity integrin binding proteins$130,831
K01 · FY2004 · CA
Engineering enhanced EGF mutants by directed evolution$41,608
F32 · FY2003 · CA
Engineering enhanced EGF mutants by directed evolution$11,605
F32 · FY2003 · CA
Engineering enhanced EGF mutants by directed evolution$33,260
F32 · FY2001 · CA